Ravulizumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized (from mouse) |
| Target | complement C5 |
| Clinical data | |
| Other names | ALXN1210 |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6430H9888N1696O2028S48 |
| Molar mass | 144.9 g/mol g·mol−1 |
Ravulizumab (ALXN1210) (INN[2]) is a humanized monoclonal antibody designed for the treatment of paroxysmal nocturnal hemaglobinuria and atypical hemolytic uremic syndrome.
This drug was developed by Alexion Pharmaceuticals, Inc.[3]
It is currently at Phase III trials.
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Ravulizumab, American Medical Association.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |